Severe hepatic or severe renal impairment: Recommended dose is 50 mg if needed, a second 50 mg dose may be taken at least 2 hours after the initial dose 1. Dose adjustment is recommended with concomitant use of UBRELVY and moderate CYP3A4 inhibitors including cyclosporine, ciprofloxacin, fluconazole, fluvoxamine, and with grapefruit juice.Avoid use in patients with end-stage renal disease 1.See Section 2.2 of the Prescribing Information 1 Patients on moderate or weak CYP3A4 inhibitors or inducers or BCRP and/or P-gp only inhibitors will require dose modifications.Strong CYP3A4 inducers should be avoided as concomitant use will result in reduction of UBRELVY exposure 1.UBRELVY should not be used concomitantly with strong CYP3A4 inhibitors, such as ketoconazole, itraconazole, or clarithromycin, as they will cause an increase in UBRELVY exposure 1.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |